Gubra Q3 2026 EBIT swings to profit of DKK 317.7 million year-on-year
Bitget2026/11/06 06:02- Gubra swung to Q3 2026 EBIT of DKK 317.7 million from an operating loss a year earlier.
- Revenue rose year-on-year to DKK 447.7 million; Biotech revenue benefited from partner milestone payments.
- AbbVie and Boehringer Ingelheim advanced partnered obesity programs into Phase 2 development.
- Gubra initiated a Phase 1/2a trial of its proprietary GUB-UCN2 program targeting healthier body composition.
- Full-year 2026 CRO guidance narrowed to 2-6% revenue growth and a 10-13% EBIT margin.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Asia-Pacific stock markets follow the overnight rally in US tech stocks, with South Korea's KOSPI up 5% at the open, SK Hynix surging more than 7%, and Nikkei 225 rising over 2%.
This round of rebound occurred after the market experienced severe turbulence. Last week, concerns over the potential for stricter regulation of the artificial intelligence industry, due to the US Congressional election results, triggered a large-scale sell-off in chip stocks. Several market participants believe that this rebound indicates investors have not abandoned the AI trading narrative, and last week’s sell-off was more about position adjustments rather than a trend reversal.
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
